BriaCell Therapeutics (BCTX)
Develops HLA-matched cell immunotherapies for metastatic breast cancer and other solid tumors.
Something off on this page? Send us feedback.
Develops HLA-matched, off-the-shelf whole-cell immunotherapies for metastatic breast cancer and other solid tumors. With no approved products or product revenue, operations concentrate on Bria-IMT’s pivotal trial and external clinical, manufacturing, and drug-supply partners.
Develops allogeneic whole-cell immunotherapies for metastatic breast cancer and other solid tumors. Its lead regimen, Bria-IMT, combines a genetically engineered breast-cancer cell line with cyclophosphamide, interferon-alpha, and retifanlimab in a pivotal randomized study. Bria-OTS and related programs extend HLA-matched, premanufactured cell-therapy designs to breast, prostate, lung, melanoma, and ovarian cancers.
Operates as one immuno-oncology R&D segment with no approved products or product revenue. Corporate activity spans West Vancouver and Philadelphia, while clinical materials and trial execution depend on external manufacturers, drug suppliers, and service partners. Future commercial capability depends on regulatory approval, scalable cGMP supply, enrollment, and financing.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Apr 30, 2026Cash & short-term investments $22.8M · Total debt $0 · Total assets $27.1M · Shareholders' equity $24.1M
- Revenue
- $0
- Operating income
- −$7.6M
- Net income
- −$7.2M
No dividends on record.
| Institutions14 holders · as of Mar 31, 2026 | 4.44% | 386.7K shares | |
| Strategic holders1 holder · as of Jan 23, 2026 | 8.24% | 716.7K shares | |
| Otherremainder | 87.32% | 7.60M shares |
8.70M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Citadel Advisors LLCStrategic | 8.24% | 716,699 | 13Gfiled Jan 23, 2026 ↗ |
Cable Car Capital LLCInstitution | 2.49% | 216,821 | 13Fas of Mar 31, 2026 |
Sabby Management, LLCInstitution | 0.85% | 73,915 | 13Fas of Mar 31, 2026 |
Iridian Asset Management LLC/CTInstitution | 0.75% | 65,000 | 13Fas of Mar 31, 2026 |
Luminarx Capital Management LPInstitution | 0.17% | 15,000 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
Nothing filed in the last 12 months.
- Gilead Sciences
TRODELVY is a direct late-line metastatic breast-cancer alternative.
- AstraZeneca (ADR)
Co-developer of ENHERTU and DATROWAY in metastatic breast cancer.
- Merck
KEYTRUDA is a major PD-1 option in metastatic triple-negative breast cancer.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| BriaCell Therapeutics | $3.57 | −0.28% | $31.1M | — | — | — | — |
| Gilead Sciences | $149.61 | 0.00% | $185.75B | — | 16.5 | 6.1 | +10.2% |
| AstraZeneca (ADR) | $164.17 | +1.55% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Merck | $151.96 | +0.21% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| Median | 72.8 | 16.5 | 5.6 | +6.4% |